With the help of extraordinary findings and growth in relation with Cystic Fibrosis, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has made a lot of money and grabbed everyone’s attention in the recent past. But it’s Spyryx Biosciences that has come up with the latest updates. As per the reports, Spyryx claims to have discovered a way to treat all types of CF with a single therapy. It has recently raised $18 million to initiate advance research in this field and reach a meaningful conclusion.
Spyryx’s Achievements So Far:
The company was founded in 2013 with an objective to unearth some of the rarest issues in the bioscience field. It focuses on fleshing out the extraordinary work of Robert Tarran, Professor, University of North Carolina. Tarran is the one who located an important link between the airway dehydration and the regulatory protein SPLUNC1. Scientists believe that airway dehydration leads to the deadly pulmonary symptoms of CF.
As per the reports, the human body makes use of SPLUNC1 to modulate the quantity of fluid that is absorbed in the airways. It also crafts a peptide therapy that mimics the effects of protein. Spyryx strongly believes that it has hit upon a never-before-used way to reverse all the characteristic dehydration of CF. The doctors have used a lot of targeted therapies like Kalydeco of Vertex to get rid of hundreds of problems in the past. These therapies have a good scope in the future as well.
The only problem with such therapies is that they work on those patients those genetic mutations. The number of such patients is not more than 5%, which is a sign of worry for the health experts. It forms a perfect ground for any such therapy that can get rid of all types of CFs singlehandedly. Spyryx hopes that it will manage to come up with a feasible solution for different types of CFs in the future.
